Drug Trial Radar · NCT04539951
Pragmatic Trial of Obsessive-compulsive Disorder
Last checked: Nov 19, 2026Latest source record: May 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,600
Planned (sponsor's estimate)
Start
Sep 22, 2020
Primary completion
Jun 30, 2027
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Shanghai Mental Health CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- First Affiliated Hospital of Harbin Medical University; Guizhou Provincial People's Hospital; First Affiliated Hospital of Jinan University; West China Hospital; Suzhou Psychiatric Hospital; Nanjing Medical University; Wuhan Mental Health Centre; Seventh People's Hospital of Hangzhou; First Affiliated Hospital of Kunming Medical University; General Hospital of Ningxia Medical University; The First Affiliated Hospital of Nanchang University; The Second Affiliated Hospital of Xinxiang Medical University
- First posted
- Sep 7, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study includes a sequenced clinical trial in order to assess the efficacy of several switching or augment strategies when initial treatment is ineffective,and to provide strong evidence for clinical practice and international guidelines for Obsessive-Compulsive Disorder treatments.
Conditions
- Obsessive-Compulsive Disorder
Interventions
Sertraline 200 milligram(mg)Drug
All included participants will receive sertraline, initially at 50mg/d, with a weekly 50mg/d further increase, to the maximum recommended dosage (200mg/d) or to the maximum tolerated dosage (less than 200mg/d). Patients will be on their maximum dose by week 4, so allowing an assessment of response at 12 weeks
Sertraline 300 milligram(mg)Drug
In experimental phase II, the patients in this group will remain on sertraline (higher dosage): where sertraline 200mg has been tolerated, dosage will be increased by 50mg fortnightly to a maximal dose of 300mg/d or to the maximum tolerable dose (less than 300mg/d).
FluvoxamineDrug
Fluvoxamine will be initiated at a dose of 50mg/d, increasing quickly to a maximal dose of 300mg/d or the maximum tolerated dose by week 4.
VenlafaxineDrug
venlafaxine will be initiated at 75mg/d, increasingly weekly by 75mg/day, to a maximal dose of 300 mg/d or the maximum tolerated dose.
Augment with MemantineDrug
Sertraline will be augmented with memantine initially at 5mg/d, and increasing by 5mg/d weekly to a maximal dose of 20mg/d (10mg twice daily) or the maximum tolerated dose
Augment with AripiprazoleDrug
Sertraline will be augmented with aripiprazole, initially at 5mg/d, and increasing by 5mg/d weekly to a maximal dose of 20mg/d or the maximum tolerated dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Yale-Brown Obsessive-Compulsive Scale (Y-BOCS)Time frame: from baseline to 12 weeks, and 12 weeks to month 6.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Mental Health Center
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.